Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Offering SPR-BLI Services - Proteins provided for free!
Here come GMP Grade Cytokines!Free Sample is available! Here come GMP Grade Cytokines!Free Sample is available!
Expression analysis of human ErbB3 on HEK293/Human ErbB3 Stable Cell Line by FACS.
Cell surface staining was performed on HEK293/Human ErbB3 Stable Cell Line or negative control cell using PE-labeled anti-human ErbB3 antibody.
Immobilized Biotinylated Human ErbB3, His,Avitag (Cat. No. ER3-H82E6) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Human NRG1 Beta 1, Fc Tag, premium grade (Cat. No. NR1-H5268) with a linear range of 0.2-3 ng/mL (QC tested).
The purity of Mouse ErbB3, His Tag (Cat. No. ER3-M52H5) is more than 85% and the molecular weight of this protein is around 75-110 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Osimertinib Mesylate | AZD-9291; RDL94R2A16; AZD-9291 Mesylate; AZD9291 | Approved | Astrazeneca Pharmaceutical Co Ltd | 泰瑞沙, Tagrisso | Mainland China | Carcinoma, Non-Small-Cell Lung | Astrazeneca Ab | 2015-11-13 | Uterine Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Meningeal Neoplasms; Colorectal Neoplasms; Carcinoma, Squamous Cell; Lung Neoplasms; Brain metastases; Esophageal adenocarcinoma; Cholangiocarcinoma; Lymphoma; Glioma; Endometrial Neoplasms; Thyroid Neoplasms; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Adenocarcinoma of Lung; Liver Neoplasms; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Rectal Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Solid tumours; Carcinoma, Ovarian Epithelial; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Skin Neoplasms; Colonic Neoplasms; Glioblastoma; Multiple Myeloma; Urinary Bladder Neoplasms | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Recombinat humanized HER3-targeting antibody | Phase 1 Clinical | Shanghai Institute Of Biological Products Co Ltd | Solid tumours | Details | |
Sirotinib Maleate | XZP-5491 | Phase 1 Clinical | Shandong Xuanzhu Pharmaceutical Technology Co Ltd | Stomach Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung | Details |
GSK-2849330 | GSK-2849330 | Glaxosmithkline Plc | Details | ||
JK-07 | JK-07 | Shenzhen Salubris Pharmaceuticals Co Ltd | Details | ||
Patritumab | AMG-888; U3-1287 | Amgen Inc, Daiichi Sankyo Co Ltd | Details | ||
AV-203 | AV-203; CAN-017 | Phase 1 Clinical | Aveo | Neoplasms | Details |
MP-0274 | DARPin-41; SPA-28; CME-114; CME-115; CME-118; CME-119; MP-0274 | Molecular Partners Ag | Details | ||
Recombinant Human Neuromodulin 1-Anti-HER3 Antibody Fusion Protein(Salubris) | SAL-007 | Phase 1 Clinical | Shenzhen Salubris Pharmaceuticals Co Ltd | Heart Failure | Details |
Recombinant human ErbB3 fragment vaccine (Zensun) | rhErbB3-f | Phase 1 Clinical | Zensun (Shanghai) Sci&Tech Co Ltd | Neoplasms | Details |
Allitinib Tosylate | AST-6; ALS-1306; AST-1306 | Phase 2 Clinical | Shanghai Allist Pharmaceutical Technology Co Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Elgemtumab | NOV-6; LJM-716 | Phase 1 Clinical | Novartis Pharma Ag, Morphosys Ag | Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Neoplasms; Breast Neoplasms; Esophageal Squamous Cell Carcinoma | Details |
SIBP-03 | SIBP-03 | Phase 1 Clinical | Shanghai Institute Of Biological Products Co Ltd | Neoplasms | Details |
Barecetamab | ISU-104 | Phase 1 Clinical | Isu Abxis Co Ltd | Solid tumours | Details |
HMBD-001 | HMBD-001 | Phase 2 Clinical | Hummingbird Bioscience | Solid tumours; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Urinary Bladder Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
KTN-3379 | CDX-3379; KTN-3379 | Phase 2 Clinical | Medimmune | Squamous Cell Carcinoma of Head and Neck; Neoplasms; Breast Neoplasms; Thyroid Neoplasms | Details |
Sapitinib | AZD-8931 | Phase 2 Clinical | Astrazeneca Pharmaceutical Co Ltd | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
Tesevatinib | XL-647; KD-020; KD-019; EXEL-7647 | Phase 2 Clinical | Exelixis Inc | Neoplasms; Glioblastoma; Breast Neoplasms; Brain Neoplasms; Polycystic Kidney, Autosomal Dominant; Brain metastases; Polycystic Kidney, Autosomal Recessive; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
BL-B01D1 | Phase 1 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Neoplasms, Fibroepithelial; Solid tumours; Neoplasms; Digestive System Neoplasms; Breast Neoplasms; Urologic Neoplasms; Gastrointestinal Neoplasms | Details | |
Seribantumab | MM-121; SAR-256212; 1N3L70MDFX (UNII code) | Phase 2 Clinical | Merrimack Pharmaceuticals Inc | Sarcoma; Adenocarcinoma; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Uterine Neoplasms; Gallbladder Neoplasms; Lung Neoplasms; Fallopian Tube Neoplasms; Bile Duct Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Ovarian Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Urinary Bladder Neoplasms; Pancreatic Neoplasms; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Kidney Neoplasms; Head and Neck Neoplasms; Solid tumours | Details |
Patritumab Deruxtecan | U3-1402 | Phase 3 Clinical | Daiichi Sankyo Co Ltd | Breast Neoplasms; Colorectal Neoplasms; Brain metastases; Carcinoma, Non-Small-Cell Lung | Details |
Zenocutuzumab | MCLA-128 | Phase 2 Clinical | Merus Nv | Solid tumours; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Izalontamab | SI-B001; SI-1X6.4 | Phase 3 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Head and Neck Neoplasms; Solid tumours; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasms, Glandular and Epithelial; Triple Negative Breast Neoplasms; Digestive System Neoplasms; Colorectal Neoplasms; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung | Details |
This web search service is supported by Google Inc.